Haematologica 2003 - Supplements

Figure1
100%
80%
60%
40%
20%
0%
Time-To-Event Outcomes: UARK 98-026
Patients with Follow-up, Data as of 03/04/03
Overall Survival
Event-Free Survival
Events / N
82 / 541
120 / 541
4-Year
Estimate
69% (61,76)
62% (55,68)
0 1 2 3 4 5
Years from Start of Protocol Therapy
Cytogenetic abnormalities (CA), present in 35%, imparted poor
prognosis. Thus, OS and EFS were superior in the absence of CA
(4yr OS 83% and 4yr EFS 82%); however, in the presence of
CA13 or hypodiploidy, 4yr OS was only 41% and 4yr EFS 37%;
an intermediate survival was observed in patients with “other
CA” (4yr OS 59%, 4yr EFS 57%) (all p